Exhibit 99.2

MOLECULAR PROBES, INC., AND SUBSIDIARIES
UNAUDITED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and par value information)


			June 30,		September 30,
			2003		2002
ASSETS
Current Assets:
	Cash and cash equivalents		$	3,167	$	2,551
	Short-term investments			7,013		7,797
	Restricted cash			179		—
	Accounts receivable			6,525		5,263
	Inventories			5,694		4,195
	Income taxes receivable			—		1,086
	Prepaid expenses and other current assets			637		1,559

		Total current assets		23,215		22,451
Property and equipment, net				21,059		14,430
Goodwill				756		—
Other assets				673		570

Total Assets			$	45,703	$	37,451

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
	Line of credit		$	45	$	—
	Current portion of long-term obligations			400		227
	Accounts payable			715		3,202
	Accrued expenses and other current liabilities			2,610		2,460
	Income taxes payable			932		31

		Total current liabilities		4,702		5,920

Long-term obligations				11,982		9,796

Commitments and contingencies
Shareholders’ equity:
	Preferred stock, $0.001 par value; 40,000,000 shares authorized, 37,234,300 shares issued and outstanding (liquidation preference of $68,883)			37		37
	Common stock, $0.001 par value; 100,000,000 shares authorized, 37,265,540 and 37,234,300 shares issued and outstanding, respectively			37		37
	Additional paid-in capital			36		30
	Accumulated other comprehensive loss			—		(8	)
	Retained earnings			28,909		21,639

Total shareholders’ equity				29,019		21,735

Total liabilities and shareholders’ equity			$	45,703	$	37,451

MOLECULAR PROBES, INC., AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME
(In thousands)


			Nine months ended
			June 30,

			2003			2002
Revenues:
Product sales			$	44,290		$	39,315
License fees and royalty income				2,630			1,015
Research grant and contract income				431			292

				47,351			40,622
Expenses:
	Cost of revenues			7,110			6,716
	Research and development			7,471			4,919
	General and administrative			6,548			7,003
	Sales and marketing			5,770			3,491

				26,899			22,129

		Operating income		20,452			18,493

	Charitable contributions			(915	)		(920	)
	Net gains on marketable securities			102			88
	Net gains (losses) on foreign currency exchange			1,322			(166	)
	Interest income			136			209
	Interest expense			(775	)		(746	)
	Other income, net			119			26

		Other expense, net		(11	)		(1,509	)

Income before income taxes				20,441			16,984
Provision for income taxes				(7,661	)		(6,462	)

		Net income	$	12,780		$	10,522

MOLECULAR PROBES, INC., AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)


				Nine months ended
				June 30,

				2003			2002
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income				$	12,780		$	10,522
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization					1,688			1,516
Realized gain (loss) on available-for-sale securities					453			(1,336	)
Other non-cash adjustments					(22	)		1
Changes in operating assets and liabilities, net of effects of business acquired:
	Accounts receivable				(1,158	)		(1,687	)
	Inventories				(1,305	)		(525	)
	Income taxes receivable				1,086			1,638
	Prepaid expenses and other current assets				95			163
	Accounts payable and accrued liabilities				(2,331	)		(492	)
	Income taxes payable				901			3

			Net cash provided by operating activities		12,187			9,803

CASH FLOWS FROM INVESTING ACTIVITIES:
	Payments received on related party note receivable				839			833
	Capital expenditures				(5,820	)		(1,344	)
	Available-for-sale securities:
		Purchases			—			(1,478	)
		Maturities			3,379			151
	Held-to-maturity securities:
		Purchases			(4,085	)		(252	)
		Maturities			1,088			5,127
	Net cash paid for business acquisition				(1,000	)		—
	Change in other assets				(294	)		51

			Net cash provided by (used in) investing activities		(5,893	)		3,088

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the exercise of stock options					6			6
Payments of dividends					(5,511	)		(10,000	)
Payments on capital lease obligation					(173	)		(374	)

			Net cash used in financing activities		(5,678	)		(10,368	)

			Net increase in cash and cash equivalents		616			2,523
Cash and cash equivalents, beginning of period					2,551			1,571

Cash and cash equivalents, end of period				$	3,167		$	4,094

MOLECULAR PROBES, INC., AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

The consolidated financial statements include the accounts of Molecular Probes, Inc. (“Molecular Probes”) and its wholly-owned subsidiaries, Molecular Probes Europe (“MPE”) and Interfacial Dynamics Corporation. All significant intercompany accounts and transactions have been eliminated in consolidation. The interim financial statements have been prepared, without audit, according to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations. The accompanying unaudited financial statements contain all adjustments, which include only normal recurring adjustments, necessary to state fairly the financial position, results of operations and cash flows as of and for the periods indicated. Molecular Probes’ fiscal year ends September 30. The unaudited balance sheet as of September 30, 2002 is derived from the audited balance sheet included in Exhibit 99.1 herein.

These financial statements should be read in conjunction with the audited financial statements and the notes thereto included in Exhibit 99.1 herein.

Molecular Probes records revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price to the customer is fixed and determinable and collectibility is reasonably assured.

Pursuasive evidence of an arrangement exists – Molecular Probes’ business practice requires written or electronic documentation or evidence from a customer to support a sales or licensing arrangement or grant contract.

Delivery has occurred or services have been rendered – Revenue from product sales is recognized in the period the product is shipped. Products are shipped Freight on Board shipping point. Once those terms are met, Molecular Probes has no continuing obligations or performance criteria requirements. Molecular Probes has no “bill and hold” arrangements with customers.

Research and development grant and contract revenues are recognized in accordance with the terms of the related agreements, generally as qualified research activities progress. Payments received for future performances are deferred and recorded as revenue when earned.

License fees are recognized when there is no material continuing performance obligation under the agreement. Up-front payments are deferred and recorded as revenue over the term of the agreement.

Fixed or determinable price – Sales of Molecular Probes products are at fixed or established sales prices determined prior to the time the products are shipped with no customer cancellation, price protection or termination clauses.

Collectibility is reasonably assured – Based on Molecular Probes’ credit management policies it believes collectibility is reasonably assured (1) when product is shipped to a customer; (2) as qualified research activities progress and revenues become billable under research and development grants and contracts; and (3) when there is no continuing performance obligations under licensing arrangements. Based on the Molecular Probes’ historical experience, no provision for uncollectible accounts and return allowances are necessary at the time revenue is recognized.

Molecular Probes accounts for its employee stock option plans under the recognition and measurement principles of APB Opinion No. 25, “Accounting for Stock Issued to Employees,” and has adopted the disclosure only provisions of Statement of Financial Accounting Standards No. 123, “Accounting for Stock-Based Compensation” (SFAS No. 123). Accordingly, no compensation cost has been recognized for the fixed stock option plans under the fair value recognition provisions of SFAS No. 123. In December 2002, the FASB issued SFAS No. 148, Accounting for Stock-Based Compensation – Transition and Disclosure, which is effective for fiscal years ending after December 31, 2002. SFAS No. 148 amends SFAS No. 123, Accounting for Stock-Based Compensation, to provide alternative methods of transition to SFAS No. 123’s fair value method of accounting for stock-based employee compensation. SFAS No. 148 also amends the disclosure provisions of SFAS No. 123 and Accounting Principles Board (APB) Opinion No. 28, Interim Financial Reporting, to require disclosure in the summary of significant accounting policies of the effect of an entity’s accounting policy with respect to stock-based employee compensation on reported net income in annual and interim financial statements. Molecular Probes adopted SFAS No. 148 for the nine months ended June 30, 2003. The following table illustrates the effect on net income if Molecular Probes had applied the fair value recognition provisions of SFAS No. 123 to stock-based employee compensation.


	For the Nine Months
(in thousands)	Ended June 30,

	2003			2002
Net income, as reported	$	12,780		$	10,522
Deduct: total stock-based employee compensation expense determined under fair value based method for all stock options, net of related tax effects		(111	)		(60	)

Pro forma net income	$	12,669		$	10,462

On April 8, 2003, Molecular Probes acquired all of the outstanding common stock of Interfacial Dynamics Corporation for $1.0 million. The transaction has been accounted for as a purchase, and, accordingly, the results of operations have been included in the accompanying consolidated financial statements from the date of acquisition. Molecular Probes incurred approximately $45,000 of closing costs for this acquisition. The excess of purchase price over the acquired net assets was $0.8 million at June 30, 2003, and has been recorded as goodwill in the Unaudited Consolidated Balance Sheet.

Accumulated depreciation of property and equipment was $9.9 million and $8.2 million at June 30, 2003 and September 30, 2002, respectively.

Total dividends paid to common stock holders for the nine months ended June 30, 2003 and 2002 were $5.5 million and $10.0 million, respectively.

On May 24, 2002, RAM LLC, a related party, entered into a line of credit agreement for the construction of a new facility. The $2.0 million note is collateralized by the new facility and guaranteed by Molecular Probes. In conjunction with the acquisition of Molecular Probes, as described in the subsequent event in Note 9 below, this guarantee was terminated.

Molecular Probes is a party to various claims, disputes, legal actions and other proceedings involving contracts, employment and various other matters. The outcome of these matters is not expected to have a material effect on the consolidated financial condition of Molecular Probes.

On August 20, 2003, Invitrogen Corporation (“Invitrogen”) acquired all of the outstanding shares of common stock of Molecular Probes for cash of $303.9 million. Just prior to the acquisition, each outstanding share of preferred stock was converted into one equivalent share of common stock. Stock options of Molecular Probes were also assumed by Invitrogen. Each option to purchase one share of common stock of Molecular Probes was converted into an option to purchase one share of Invitrogen common stock based on an exchange rate of 0.0756037.